/

Empresas

An

No verificado

Anaveon

Sobre qué escribimos

Farmacéutica

5 Comunicados de prensa

Ver todos los comunicados de prensa

28/05/2026

Farmacéutica

Anaveon Reports Clinical Benefit of ANV600 in the EXPAND-1 Phase 1 Clinical Trial at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio

Fuente

Editor

1.00

0

19/05/2026

Farmacéutica

Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer

Fuente

Editor

1.00

0

13/05/2026

Farmacéutica

Anaveon Appoints Thomas P. Mathers as Chair of the Board of Directors

Fuente

Editor

1.00

0

11/05/2026

Farmacéutica

Anaveon Announces Presentation of Positive ANV600 Clinical Data at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio

Fuente

Editor

1.00

0

23/03/2026

Farmacéutica

Anaveon appoints Biotech Leader Thaminda Ramanayake as Chief Executive Officer

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0